Zinc hyaluronate 0.15% eye drops preservative free
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 22 studies.
Reviews & meta-analyses: 1 · 1988–2026
Showing all 22 studies, sorted by most relevant.
Qinglin Wu, Zuqing Wu, Zhifu Lu
2023
Yiming Xiang, Jiali Lu, Congyang Mao, et al.
Science Advances, 2023
- Acne Vulgaris
- Bacterial Infections
- Anti-Bacterial Agents
Acne is an inflammatory skin disease mainly caused by Propionibacterium acnes , which can cause local inflammatory reactions and develop into chronic inflammatory diseases in severe cases. To avoid the use of antibiotics and to effectively treat the site of acne, we report a sodium hyaluronate microneedle patch that mediates the transdermal delivery of ultrasound-responsive nanoparticles for the effective treatment of acne. The patch contains nanoparticles formed by zinc porphyrin–based metal-organic framework and zinc oxide (ZnTCPP@ZnO). We demonstrated activated oxygen-mediated killing of P. acnes with an antibacterial efficiency of 99.73% under 15 min of ultrasound irradiation, resulting in a decrease in levels of acne-related factors, including tumor necrosis factor–α, interleukins, and matrix metalloproteinases. The zinc ions up-regulated DNA replication–related genes, promoting the proliferation of fibroblasts and, consequently, skin repair. This research leads to a highly effective strategy for acne treatment through the interface engineering of ultrasound response.
Abstract licence: CC BY-NC
K. Surendrakumar, G. Martyn, E. C. M. Hodgers, et al.
Journal of controlled release : official journal of the Controlled Release Society, 2003
- Administration, Inhalation
- Chemistry, Pharmaceutical
- Delayed-Action Preparations
Cem Özel, C. B. Çevlik, A. Özarslan, et al.
International journal of biological macromolecules, 2023
- Hyaluronic Acid
- Zinc
- Glass
Shawn J. Green, Guido Tarone, Charles B. Underhill
Journal of Cell Science, 1988
- Basement Membrane
- Epithelium
- Cricetinae
Taofeng Li, Suxia Yan, Hongyu Dong, et al.
Journal of colloid and interface science, 2023
Boglárka Szalai, Mária Budai-Szűcs, A. Kovács, et al.
International journal of pharmaceutics, 2024
- 2-Hydroxypropyl-beta-cyclodextrin
- Dexamethasone
- Gels
Dexamethasone (DXM) is a commonly used corticosteroid in the treatment of ocular inflammatory conditions that affect more and more people. The aim of this study was to evaluate the effect of the combination of hydroxypropyl-β-cyclodextrin (HPBCD), in situ gelling formulations, and other mucoadhesive polymers, i.e., hydroxypropyl methylcellulose (HPMC) and zinc-hyaluronate (ZnHA), on permeation by applying in vitro and ex vivo ophthalmic permeation models. Additionally, gelling properties, in vitro drug release, and mucoadhesion were measured to determine the impact of these factors on permeation and ultimately on bioavailability. The results showed that GEL1 and GEL2 had an optimal gelling temperature, 36.3 ℃ and 34.6 ℃, respectively. Moreover, the combination of Poloxamer 407 (P407) with other polymers improved the mucoadhesion (GEL1: 1333.7 mN) compared with formulations containing only P407 (P12: 721.8 mN). Both HPBCD and the gel matrix had a considerable influence on the drug release and permeability of DXM, and the combination could facilitate the permeation into the aqueous humor. After 30 min of treatment, the DXM concentration in the aqueous humor was 1.16-1.37 µg∕mL in case of the gels, whereas DXM could not be detected when treated with the DXM suspension. The results of the experiments using an in vitro cell line indicated that the formulations could be considered safe for topical treatment of the eye. In conclusion, with application of a small amount of HPMC (0.2 % w∕w), the concentration of P407 could be reduced to 12 % w/w while maintaining the ideal gelling properties and gel structure without negatively affecting permeability compared with the formulation containing a higher amount of P407. Furthermore, the gel matrix may also provide programmed and elongated drug release.
Abstract licence: CC BY-NC-ND
Rabia Ashfaq, Nóra Tóth, A. Kovács, et al.
Pharmaceutics, 2025
Objectives: This study aimed to develop and evaluate nanostructured lipid carriers (NLCs) loaded with meloxicam (Melox) and a therapeutic antibacterial and anti-inflammatory liquid lipid, clove oil (CO) for periodontitis treatment, a complex inflammatory condition necessitating advanced drug delivery systems. The NLC–Melox formulation was integrated into three hydrogels, hypromellose (HPMC), zinc hyaluronate (ZnHA), and sodium hyaluronate (NaHA), to conduct a comparative analysis focusing on enhanced localized drug delivery, improved mucoadhesion, prolonged retention, and significant therapeutic outcomes. Methods: NLC–Melox was prepared by homogenization and characterized by dynamic light scattering (DLS). Subsequently, NLC–Melox-loaded gels were subjected to transmission electron microscopy (TEM), differential scanning calorimetry (DSC), X-ray diffraction (XRD), Raman spectroscopy, and rheological analysis. In vitro drug release, anti-inflammatory activity (BSA denaturation assay), and antibacterial efficacy (MIC, MBC) were investigated to assess therapeutic potential. Results: DLS revealed a particle size of 183 nm with a polydispersity index of 0.26, indicating homogeneity. TEM confirmed consistent morphology and uniform nanoparticle distribution. DSC and XRD demonstrated the amorphous nature of Melox, enhancing solubility and stability. Spectroscopy confirmed no chemical interactions between components. Rheological studies identified ZnHA as the most mucoadhesive and structurally stable gel. In vitro release studies showed sustained drug release over 24 h. Melox and CO-loaded formulations demonstrated significant anti-inflammatory activity and notable antibacterial efficacy due to the antibacterial oil. Conclusions: The study highlighted the potential of NLC-based mucoadhesive hydrogels as an effective strategy for periodontitis treatment. The formulation offered improved drug solubility, therapeutic efficacy, mucoadhesivity, and prolonged delivery, making it a promising candidate for localized therapy.
Abstract licence: CC BY
Fang-zhou Chen, Zhaowenbin Zhang, Qingfeng Li, et al.
Biomaterials Research, 2025
UVR-related skin damage is common in daily life. Excessive sunlight exposure, particularly in response to ultraviolet B (UVB) radiation, can have adverse effects on the skin and can even induce photosensitive skin diseases and skin malignancies. UVB exposure leads to the production of reactive oxygen species (ROS) in the skin, resulting in cell damage and inflammation. Furthermore, it directly inhibits the synthesis of collagen in skin fibroblasts, contributing to collagen degradation and subsequently causing skin aging, wrinkles, and erythema. To address this issue, our study introduces a biomaterial-based treatment plan for repairing UVB-induced photodamaged skin. We designed a sodium hyaluronate microneedle patch containing a hardystonite bioceramic (ZnCS/MN) with anti-ROS/inflammation/collagen degradation functions to deliver bioactive Zn 2+ and SiO 3 2− ions in situ to photodamaged skin areas. In addition, the cytological mechanism of ZnCS action was explored to explore the possibilities of its application in more areas. This study reveals the therapeutic potential of ZnCS for a variety of negative effects caused by photodamage. Owing to its advantages in preparation, storage, and transportation, ZnCS/MN has shown promise for clinical application in treating photodamaging.
Abstract licence: CC BY
Xuhui Li, Baoyue Zhang, Chuxing Jiang, et al.
Journal of Power Sources, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.